Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Pegargiminase (ADI-PEG 20), Venetoclax and Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Brittany Knick Ragon, Justin M. Watts, John Bomalaski, Amanda Johnston, Mirla Langlois, Nicole DeFord Chang, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 6000.

https://doi.org/10.1182/blood-2024-201074

Published: 2024

Journal Articles

Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Zalak Shah, Danielle Boselli, Stephanie Begley, Rupali Bose, Yifan Pang, Srinivasa Reddy Sanikommu, Nilay A. Shah, Aleksander L. Chojecki, Thomas G. Knight, Jing Ai, Belinda Avalos, Edward A. Copelan, Michael R. Grunwald, Brittany Knick Ragon

Blood (2024) 144 (Supplement 1): 5194.

https://doi.org/10.1182/blood-2024-201054

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Infusion Immediate Care: Improving Hematology/Oncology Practice Quality through Expanded and Timely Access to Infusion Care

Melissa Barnes, Christina Villa, Brenda Crump, Donna Field, Seungjean Chai, Ruben A. Mesa, Payal Desai, Sridhar Pal, Jennifer Gray, Brittany Knick Ragon

Blood (2024) 144 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2024-200106

Published: 2024

Journal Articles

A Phase 1A/B Combination Study of Pegargiminase (ADI-PEG 20), Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

Brittany Knick Ragon, John Bomalaski, Amanda Johnston, Mirla Langlois, Nicole DeFord Chang, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 1554.

https://doi.org/10.1182/blood-2023-174954

Published: 2023

Journal Articles

Socioeconomic Disadvantage Is Associated with Decreased Long-Term Survival in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia

Allison Verbyla, Danielle Boselli, Brittany Knick Ragon, Jing Ai, Lawrence J. Druhan, Meng-Yun Lin, Michael R. Grunwald, Amresh Hanchate, Thomas G. Knight

Blood (2023) 142 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2023-182299

Published: 2023

Journal Articles

Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia

Thomas G. Knight, Danielle Boselli, Allison Verbyla, Jing Ai, Aleksander L. Chojecki, Nilay Shah, Yifan Pang, Lawrence J. Druhan, Edward A. Copelan, Michael R. Grunwald, Brittany Knick Ragon

Blood (2023) 142 (Supplement 1): 5078.

https://doi.org/10.1182/blood-2023-182371

Published: 2023

Journal Articles

Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay Shah, Aleksander L. Chojecki, Srinivasa Reddy Sanikommu, Yifan Pang, Jing Ai, Belinda Avalos, Edward A. Copelan, Thomas G. Knight, Michael R. Grunwald

Blood (2023) 142 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2023-179352

Published: 2023

Journal Articles

MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia

Brittany Knick Ragon, Margaret D. Templeton, Sara L. Seegers, Jenny Chen, Hsih-Te Yang, Thomas G. Knight, Jing Ai, Edward A. Copelan, Belinda Avalos, Nury M. Steuerwald, Jian Jin, Gang Greg Wang, Steven I. Park, Jai N. Patel, Michael R. Grunwald, Lawrence J. Druhan

Blood (2023) 142 (Supplement 1): 5741.

https://doi.org/10.1182/blood-2023-179318

Published: 2023

Journal Articles

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss

Blood (2022) 140 (Supplement 1): 3284–3286.

https://doi.org/10.1182/blood-2022-162525

Published: 2022

Journal Articles

Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay A. Shah, Aleksander L. Chojecki, Srinivasa Reddy R. Sanikommu, Jing Ai, Lawrence J Druhan, Nury M Steuerwald, Jai N Patel, James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Derek Raghavan, Thomas G. Knight, Michael R. Grunwald

Blood (2022) 140 (Supplement 1): 10993–10995.

https://doi.org/10.1182/blood-2022-159179

Published: 2022

Journal Articles

Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience

Rushil V. Patel, Danielle Boselli, Patrick L Meadors, Stephanie Begley, Rupali Bose, Jing Ai, Brittany Knick Ragon, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Thomas G. Knight, James T. Symanowski, Declan Walsh, Michael R. Grunwald, Aleksander L. Chojecki

Blood (2022) 140 (Supplement 1): 5279–5280.

https://doi.org/10.1182/blood-2022-156494

Published: 2022

Journal Articles

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Aleksander L. Chojecki, Jai N. Patel, David M Foureau, James Symanowski, Xhevahire Begic, Michael Davis, Nury M Steuerwald, Sarah Norek, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Brittany Knick Ragon, Thomas G. Knight, Jing Ai, Michael R. Grunwald, Nilanjan Ghosh, Lawrence J Druhan, Belinda R. Avalos, Edward A. Copelan

Blood (2022) 140 (Supplement 1): 10534–10536.

https://doi.org/10.1182/blood-2022-160214

Published: 2022

Journal Articles

Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Blood (2022) 140 (Supplement 1): 11530–11531.

https://doi.org/10.1182/blood-2022-166277

Published: 2022

Journal Articles

Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Thomas G. Knight, James T. Symanowski, Jing Ai, Brittany Knick Ragon, Aleksander L. Chojecki, Nilay A. Shah, Srinivasa Reddy Sanikommu, Edward A. Copelan, Declan Walsh, Michael R. Grunwald, Patrick L Meadors

Blood (2022) 140 (Supplement 1): 8144–8145.

https://doi.org/10.1182/blood-2022-168973

Published: 2022

Journal Articles

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Aleksander L. Chojecki, Justin Arnall, Danielle Boselli, Kristyn Y. DiSogra, Allison Karabinos, Tommy Chen, Jing Ai, Thomas G. Knight, Brittany Knick Ragon, Nilay A. Shah, Srinivasa R. Sanikommu, James T Symanowski, Belinda R Avalos, Edward A. Copelan, Michael R. Grunwald

Blood (2021) 138 (Supplement 1): 1252.

https://doi.org/10.1182/blood-2021-149811

Published: 2021

Journal Articles

Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration

Pavan Tenneti, Jiaxian He, Brittany Knick Ragon, Nilay A. Shah, Jing Ai, Aleksander L. Chojecki, Thomas G. Knight, Belinda Avalos, Edward A. Copelan, Michael R. Grunwald, Srinivasa Reddy R. Sanikommu

Blood (2021) 138 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2021-154011

Published: 2021

Journal Articles

Platform Incorporating Patient Navigation, Preparative Guidelines, and Hospital at Home May Improve COVID-19 Outcomes for Patients with Myeloid Malignancies

Blood (2021) 138 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2021-150610

Published: 2021

Journal Articles

Functional Proteomic Profiling of Myelodysplastic Syndromes Reveals Distinct Protein Expression Signatures and Identifies Candidate Therapeutic Targets

Brittany Knick Ragon, MD, Fieke W Hoff, Chenyue W Hu, Yihua Qiu, MD, Suk-Young Yoo, Amina Qutub, Steven M. Kornblau, MD

Blood (2016) 128 (22): 1975.

https://doi.org/10.1182/blood.V128.22.1975.1975

Published: 2016

Journal Articles

Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents

Brittany Knick Ragon, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Maro Ohanian, DO, Alessandra Ferrajoli, MD, Naveen Pemmaraju, MD, Hagop M Kantarjian, MD, Gautam Borthakur, MD

Blood (2015) 126 (23): 2604.

https://doi.org/10.1182/blood.V126.23.2604.2604

Published: 2015

NARROW

Pegargiminase (ADI-PEG 20), Venetoclax and Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Infusion Immediate Care: Improving Hematology/Oncology Practice Quality through Expanded and Timely Access to Infusion Care

A Phase 1A/B Combination Study of Pegargiminase (ADI-PEG 20), Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

Socioeconomic Disadvantage Is Associated with Decreased Long-Term Survival in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia

Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia

Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration

Platform Incorporating Patient Navigation, Preparative Guidelines, and Hospital at Home May Improve COVID-19 Outcomes for Patients with Myeloid Malignancies

Functional Proteomic Profiling of Myelodysplastic Syndromes Reveals Distinct Protein Expression Signatures and Identifies Candidate Therapeutic Targets

Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only